# Phase 1 Study of Mesothelin-ADC

> **NCT02884726** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 8 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** BMS-986148

## Key facts

- **NCT ID:** NCT02884726
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-14
- **Primary completion:** 2017-09-06
- **Final completion:** 2017-09-06
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2020-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02884726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02884726, "Phase 1 Study of Mesothelin-ADC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02884726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*